Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Int J Mol Sci ; 25(15)2024 Aug 01.
Article in English | MEDLINE | ID: mdl-39125999

ABSTRACT

Elastin, a key structural protein essential for the elasticity of the skin and elastogenic tissues, degrades with age. Replenishing elastin holds promise for anti-aging cosmetics and the supplementation of elastic activities of the cardiovascular system. We employed RiboScreenTM, a technology for identifying molecules that enhance the production of specific proteins, to target the production of tropoelastin. We make use of RiboScreenTM in two crucial steps: first, to pinpoint a target ribosomal protein (TRP), which acts as a switch to increase the production of the protein of interest (POI), and second, to identify small molecules that activate this ribosomal protein switch. Using RiboScreenTM, we identified ribosomal protein L40, henceforth eL40, as a TRP switch to boost tropoelastin production. Drug discovery identified a small-molecule hit that binds to eL40. In-cell treatment demonstrated activity of the eL40 ligand and delivered increased tropoelastin production levels in a dose-dependent manner. Thus, we demonstrate that RiboScreenTM can successfully identify a small-molecule hit capable of selectively enhancing tropoelastin production. This compound has the potential to be developed for topical or systemic applications to promote skin rejuvenation and to supplement elastic functionality within the cardiovascular system.


Subject(s)
Elastin , Ribosomal Proteins , Ribosomes , Tropoelastin , Tropoelastin/metabolism , Tropoelastin/genetics , Humans , Ribosomal Proteins/metabolism , Ribosomal Proteins/genetics , Elastin/metabolism , Elastin/genetics , Ribosomes/metabolism , Ribosomes/drug effects , Ligands , Small Molecule Libraries/pharmacology
2.
Skin Pharmacol Physiol ; 34(4): 167-182, 2021.
Article in English | MEDLINE | ID: mdl-33823521

ABSTRACT

INTRODUCTION: Epidermolysis bullosa (EB) describes a family of rare genetic blistering skin disorders. Various subtypes are clinically and genetically heterogeneous, and a lethal postpartum form of EB is the generalized severe junctional EB (gs-JEB). gs-JEB is mainly caused by premature termination codon (PTC) mutations in the skin anchor protein LAMB3 (laminin subunit beta-3) gene. The ribosome in majority of translational reads of LAMB3PTC mRNA aborts protein synthesis at the PTC signal, with production of a truncated, nonfunctional protein. This leaves an endogenous readthrough mechanism needed for production of functional full-length Lamb3 protein albeit at insufficient levels. Here, we report on the development of drugs targeting ribosomal protein L35 (rpL35), a ribosomal modifier for customized increase in production of full-length Lamb3 protein from a LAMB3PTC mRNA. METHODS: Molecular docking studies were employed to identify small molecules binding to human rpL35. Molecular determinants of small molecule binding to rpL35 were further characterized by titration of the protein with these ligands as monitored by nuclear magnetic resonance (NMR) spectroscopy in solution. Changes in NMR chemical shifts were used to map the docking sites for small molecules onto the 3D structure of the rpL35. RESULTS: Molecular docking studies identified 2 FDA-approved drugs, atazanavir and artesunate, as candidate small-molecule binders of rpL35. Molecular interaction studies predicted several binding clusters for both compounds scattered throughout the rpL35 structure. NMR titration studies identified the amino acids participating in the ligand interaction. Combining docking predictions for atazanavir and artesunate with rpL35 and NMR analysis of rpL35 ligand interaction, one binding cluster located near the N-terminus of rpL35 was identified. In this region, the nonidentical binding sites for atazanavir and artesunate overlap and are accessible when rpL35 is integrated in its natural ribosomal environment. CONCLUSION: Atazanavir and artesunate were identified as candidate compounds binding to ribosomal protein rpL35 and may now be tested for their potential to trigger a rpL35 ribosomal switch to increase production of full-length Lamb3 protein from a LAMB3PTC mRNA for targeted systemic therapy in treating gs-JEB.


Subject(s)
Cell Adhesion Molecules/genetics , Epidermolysis Bullosa, Junctional/genetics , RNA, Messenger/metabolism , Ribosomal Proteins/metabolism , Artesunate/chemistry , Atazanavir Sulfate/chemistry , Epidermolysis Bullosa, Junctional/pathology , Humans , Molecular Docking Simulation , Protein Binding/physiology , Skin/pathology , Skin Physiological Phenomena , Kalinin
3.
J Dtsch Dermatol Ges ; 18(11): 1229-1235, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32776692

ABSTRACT

The care of patients with epidermolysis bullosa (EB) poses a major challenge due to the rarity, heterogeneity and complexity of the disease as well as the occurrence of numerous primary and secondary extracutaneous manifestations, causing a significant morbidity and mortality. Specialized treatment centers are essential for offering these patients adequate care, including individual, interdisciplinary coordinated treatments according to current medical standards, and access to innovative therapeutic options. Against this background, the EB House Austria was founded in 2005 and designated the first national center of expertise for genodermatoses with a focus on EB in 2017. In the same year, it became a member of the European Reference Network for Rare Skin Diseases (ERN Skin). The pillars of this institution (outpatient clinic, research unit, academy, clinical study center) interact closely with each other, with numerous national and international clinical and scientific partners, as well as with patients and their relatives via the DEBRA Austria patient group. The development of the EB House Austria as a reference center is characterized by a long-term pioneering work, which in turn could pave the way for the optimization of care for comparable diseases as well as general care structures.


Subject(s)
Epidermolysis Bullosa , Rare Diseases , Austria , Humans , Skin
4.
Acta Derm Venereol ; 96(2): 207-12, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26271044

ABSTRACT

This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.


Subject(s)
Activities of Daily Living , Biological Products/therapeutic use , Immunosuppressive Agents/therapeutic use , Psoriasis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adolescent , Adult , Aged , Aged, 80 and over , Austria , Biological Products/adverse effects , Female , Humans , Immunosuppressive Agents/adverse effects , Intention to Treat Analysis , Kaplan-Meier Estimate , Male , Middle Aged , Proportional Hazards Models , Psoriasis/diagnosis , Psoriasis/immunology , Registries , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome , Tumor Necrosis Factor-alpha/immunology , Young Adult
7.
J Am Acad Dermatol ; 70(6): 1103-26, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24690439

ABSTRACT

BACKGROUND: Several new targeted genes and clinical subtypes have been identified since publication in 2008 of the report of the last international consensus meeting on diagnosis and classification of epidermolysis bullosa (EB). As a correlate, new clinical manifestations have been seen in several subtypes previously described. OBJECTIVE: We sought to arrive at an updated consensus on the classification of EB subtypes, based on newer data, both clinical and molecular. RESULTS: In this latest consensus report, we introduce a new approach to classification ("onion skinning") that takes into account sequentially the major EB type present (based on identification of the level of skin cleavage), phenotypic characteristics (distribution and severity of disease activity; specific extracutaneous features; other), mode of inheritance, targeted protein and its relative expression in skin, gene involved and type(s) of mutation present, and--when possible--specific mutation(s) and their location(s). LIMITATIONS: This classification scheme critically takes into account all published data through June 2013. Further modifications are likely in the future, as more is learned about this group of diseases. CONCLUSION: The proposed classification scheme should be of value both to clinicians and researchers, emphasizing both clinical and molecular features of each EB subtype, and has sufficient flexibility incorporated in its structure to permit further modifications in the future.


Subject(s)
Epidermolysis Bullosa/classification , Epidermolysis Bullosa/genetics , Genetic Predisposition to Disease/epidemiology , Consensus , Epidermolysis Bullosa/diagnosis , Female , Gene Expression Regulation , Humans , Incidence , Male , Prognosis , Sensitivity and Specificity , Severity of Illness Index
8.
JID Innov ; 4(1): 100240, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38282649

ABSTRACT

Severe junctional epidermolysis bullosa is a rare genetic, postpartum lethal skin disease, predominantly caused by nonsense/premature termination codon (PTC) sequence variants in LAMB3 gene. LAMB3 encodes LAMB3, the ß subunit of epidermal-dermal skin anchor laminin 332. Most translational reads of a PTC mRNA deliver truncated, nonfunctional proteins, whereas an endogenous PTC readthrough mechanism produces full-length protein at minimal and insufficient levels. Conventional translational readthrough-inducing drugs amplify endogenous PTC readthrough; however, translational readthrough-inducing drugs are either proteotoxic or nonselective. Ribosome editing is a more selective and less toxic strategy. This technique identified ribosomal protein L35/uL29 (ie, RpL35) and RpL35-ligands repurposable drugs artesunate and atazanavir as molecular tools to increase production levels of full-length LAMB3. To evaluate ligand activity in living cells, we monitored artesunate and atazanavir treatment by dual luciferase reporter assays. Production levels of full-length LAMB3 increased up to 200% upon artesunate treatment, up to 150% upon atazanavir treatment, and up to 170% upon combinatorial treatment of RpL35 ligands at reduced drug dosage, with an unrelated PTC reporter being nonresponsive. Proof of bioactivity of RpL35 ligands in selective increase of full-length LAMB3 provides the basis for an alternative, targeted therapeutic route to replenish LAMB3 in severe junctional epidermolysis bullosa.

9.
Exp Dermatol ; 22(4): 292-4, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23528216

ABSTRACT

An important characteristic of epidermolysis bullosa simplex Dowling-Meara (EBS-DM) keratinocytes is the increased level of Jun N-terminal kinase (JNK) stress signalling, which is thought to contribute to the disease phenotype. In this work, we report on the dramatic up-regulation of cytokeratin 14 (K14) in the EBS-DM model cell line KEB7 at both the transcriptional and translational levels, which is noteworthy because KEB7 patient cells are heterozygous for a missense mutation (R125P) in K14. By performing functional assays, we show a direct link between overexpressed wild-type K14 and increased JNK signalling in healthy, immortalized keratinocytes. This observation led us to hypothesize a positive feedback model in which mutant (R125P) K14 triggers JNK signalling, leading to increased AP1-dependent expression of K14, which in turn amplifies JNK signalling further. We therefore suggest that an imbalance of cytoplasmic K14 monomers and K14 incorporated into the intermediate filament (IF) network leads to elevated stress signalling, potentially altering IF dynamics by phosphorylation, which as a side effect, weakens EBS-DM keratinocytes.


Subject(s)
Epidermolysis Bullosa Simplex/metabolism , Keratin-14/metabolism , Cell Line , Epidermolysis Bullosa Simplex/genetics , Humans , Intermediate Filaments/metabolism , Keratin-14/genetics , Keratinocytes/metabolism , MAP Kinase Signaling System , Models, Biological , Mutant Proteins/genetics , Mutant Proteins/metabolism , Mutation, Missense , Stress, Physiological , Transcription Factor AP-1/metabolism
10.
Methods ; 58(4): 376-84, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22982175

ABSTRACT

Many functional proteomic experiments make use of high-throughput technologies such as mass spectrometry combined with two-dimensional polyacrylamide gel electrophoresis and the yeast two-hybrid (Y2H) system. Currently there are even automated versions of the Y2H system available that can be used for proteome-wide research. The Y2H system has the capacity to deliver a profusion of Y2H positive colonies from a single library screen. However, subsequent analysis of these numerous primary candidates with complementary methods can be overwhelming. Therefore, a method to select the most promising candidates with strong interaction properties might be useful to reduce the number of candidates requiring further analysis. The method described here offers a new way of quantifying and rating the performance of positive Y2H candidates. The novelty lies in the detection and measurement of mRNA expression instead of proteins or conventional Y2H genetic reporters. This method correlates well with the direct genetic reporter readouts usually used in the Y2H system, and has greater sensitivity for detecting and quantifying protein-protein interactions (PPIs) than the conventional Y2H system, as demonstrated by detection of the Y2H false-negative PPI of RXR/PPARG. Approximately 20% of all proteins are not suitable for the Y2H system, the so-called autoactivators. A further advantage of this method is the possibility to evaluate molecules that usually cannot be analyzed in the Y2H system, exemplified by a VDR-LXXLL motif peptide interaction.


Subject(s)
Real-Time Polymerase Chain Reaction , Two-Hybrid System Techniques/standards , Amino Acid Motifs , Amino Acid Sequence , Gene Expression , Genes, Reporter , Peptide Library , Protein Binding , Protein Interaction Mapping/methods , Protein Interaction Mapping/standards , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reference Standards , Sensitivity and Specificity , beta-Galactosidase/metabolism
11.
Nucleic Acids Res ; 39(16): e108, 2011 Sep 01.
Article in English | MEDLINE | ID: mdl-21685452

ABSTRACT

Trans-splicing is a powerful approach to reprogram the genome. It can be used to replace 5', 3' or internal exons. The latter approach has been characterized by low efficiency, as the requirements to promote internal trans-splicing are largely uncharacterized. The trans-splicing process is induced by engineered 'RNA trans-splicing molecules' (RTMs), which target a selected pre-mRNA to be reprogrammed via two complementary binding domains. To facilitate the development of more efficient RTMs for therapeutic applications we constructed a novel fluorescence based screening system. We incorporated exon 52 of the COL17A1 gene into a GFP-based cassette system as the target exon. This exon is mutated in many patients with the devastating skin blistering disease epidermolysis bullosa. In a double transfection assay we were able to rapidly identify optimal binding domains targeted to sequences in the surrounding introns 51 and 52. The ability to replace exon 52 was then evaluated in a more endogenous context using a target containing COL17A1 exon 51-intron 51-exon 52-intron 52-exon 53. Two selected RTMs produced significantly higher levels of GFP expression in up to 61% assayed cells. This novel approach allows for rapid identification of efficient RTMs for internal exon replacement.


Subject(s)
Exons , Trans-Splicing , Autoantigens/genetics , Blotting, Western , Cell Line , Flow Cytometry , Fluorescent Dyes , Genes, Reporter , Genetic Techniques , Green Fluorescent Proteins/analysis , Green Fluorescent Proteins/genetics , HEK293 Cells , Humans , Non-Fibrillar Collagens/genetics , RNA, Messenger/metabolism , Collagen Type XVII
12.
BMC Genomics ; 13: 632, 2012 Nov 16.
Article in English | MEDLINE | ID: mdl-23157390

ABSTRACT

BACKGROUND: The Gram-negative bacterium Chlamydia pneumoniae (Cpn) is the leading intracellular human pathogen responsible for respiratory infections such as pneumonia and bronchitis. Basic and applied research in pathogen biology, especially the elaboration of new mechanism-based anti-pathogen strategies, target discovery and drug development, rely heavily on the availability of the entire set of pathogen open reading frames, the ORFeome. The ORFeome of Cpn will enable genome- and proteome-wide systematic analysis of Cpn, which will improve our understanding of the molecular networks and mechanisms underlying and governing its pathogenesis. RESULTS: Here we report the construction of a comprehensive gene collection covering 98.5% of the 1052 predicted and verified ORFs of Cpn (Chlamydia pneumoniae strain CWL029) in Gateway(®) 'entry' vectors. Based on genomic DNA isolated from the vascular chlamydial strain CV-6, we constructed an ORFeome library that contains 869 unique Gateway(®) entry clones (83% coverage) and an additional 168 PCR-verified 'pooled' entry clones, reaching an overall coverage of ~98.5% of the predicted CWL029 ORFs. The high quality of the ORFeome library was verified by PCR-gel electrophoresis and DNA sequencing, and its functionality was demonstrated by expressing panels of recombinant proteins in Escherichia coli and by genome-wide protein interaction analysis for a test set of three Cpn virulence factors in a yeast 2-hybrid system. The ORFeome is available in different configurations of resource stocks, PCR-products, purified plasmid DNA, and living cultures of E. coli harboring the desired entry clone or pooled entry clones. All resources are available in 96-well microtiterplates. CONCLUSION: This first ORFeome library for Cpn provides an essential new tool for this important pathogen. The high coverage of entry clones will enable a systems biology approach for Cpn or host-pathogen analysis. The high yield of recombinant proteins and the promising interactors for Cpn virulence factors described here demonstrate the possibilities for proteome-wide studies.


Subject(s)
Chlamydophila pneumoniae/genetics , Chlamydophila pneumoniae/pathogenicity , DNA, Bacterial , Gene Library , Genome, Bacterial , Open Reading Frames/genetics , Virulence Factors/genetics , Cloning, Molecular , Electrophoresis, Polyacrylamide Gel , Escherichia coli/genetics , Humans , Recombinant Proteins/genetics , Sequence Analysis, DNA , Two-Hybrid System Techniques , Virulence
13.
BMC Mol Biol ; 13: 18, 2012 Jun 21.
Article in English | MEDLINE | ID: mdl-22720752

ABSTRACT

BACKGROUND: The vitamin D3 receptor (VDR) is responsible for mediating the pleiotropic and, in part, cell-type-specific effects of 1,25-dihydroxyvitamin D3 (calcitriol) on the cardiovascular and the muscle system, on the bone development and maintenance, mineral homeostasis, cell proliferation, cell differentiation, vitamin D metabolism, and immune response modulation. RESULTS: Based on data obtained from genome-wide yeast two-hybrid screenings, domain mapping studies, intracellular co-localization approaches as well as reporter transcription assay measurements, we show here that the C-terminus of human PIM-1 kinase isoform2 (amino acid residues 135-313), a serine/threonine kinase of the calcium/calmodulin-regulated kinase family, directly interacts with VDR through the receptor's DNA-binding domain. We further demonstrate that PIM-1 modulates calcitriol signaling in HaCaT keratinocytes by enhancing both endogenous calcitriol response gene transcription (osteopontin) and an extrachromosomal DR3 reporter response. CONCLUSION: These results, taken together with previous reports of involvement of kinase pathways in VDR transactivation, underscore the biological relevance of this novel protein-protein interaction.


Subject(s)
Calcitriol/metabolism , Proto-Oncogene Proteins c-pim-1/metabolism , Receptors, Calcitriol/metabolism , Cell Line , Cell Nucleus/metabolism , DNA/metabolism , Humans , Protein Binding , Protein Isoforms/chemistry , Protein Isoforms/metabolism , Protein Structure, Tertiary , Proto-Oncogene Proteins c-pim-1/antagonists & inhibitors , Proto-Oncogene Proteins c-pim-1/genetics , RNA Interference , RNA, Small Interfering/metabolism , Receptors, Calcitriol/chemistry , Signal Transduction
14.
Hum Mol Genet ; 19(23): 4715-25, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-20861136

ABSTRACT

The major challenge to a successful gene therapy of autosomal dominant genetic diseases is a highly efficient and specific knock-down or repair of the disease-causing allele. In epidermolysis bullosa simplex-type Dowling-Meara (EBS-DM), a single amino acid exchange in exon 1 of the keratin 14 gene (K14) triggers a severe skin phenotype, characterized by blistering of the skin and mucous membranes after minor trauma. We chose spliceosome-mediated RNA trans-splicing to specifically replace exons 1-7 of the K14 gene. In this approach, the mutated coding region is replaced by an RNA-trans-splicing molecule (RTM) that incorporates a binding domain (BD) and the wild-type sequence of K14. Since the BD is crucial for the trans-splicing functionality, we developed a fluorescence-based RTM screen consisting of an RTM library containing random BDs. Co-transfection of the library with a target molecule enabled us to identify highly functional RTMs. The best RTMs were adapted for endogenous trans-splicing in an EBS-DM patient cell line. In this cell line, we were able to detect functional, efficient and correct trans-splicing on RNA and protein levels. Scratch assays confirmed phenotypic reversion in vitro. Owing to concomitant knock-down and repair of the mutated allele, we assume that trans-splicing is a promising tool for the treatment of autosomal dominant genetic disease.


Subject(s)
Epidermolysis Bullosa Simplex/genetics , Epidermolysis Bullosa Simplex/therapy , Keratin-14/genetics , RNA, Messenger/genetics , Trans-Splicing , Base Sequence , Blotting, Western , Cell Line , Gene Expression , Gene Library , Genetic Therapy/methods , Humans , Mutation/genetics , Phenotype , Polymerase Chain Reaction , RNA, Messenger/metabolism , Sequence Analysis, DNA , Spliceosomes/genetics
15.
Exp Dermatol ; 21(2): 111-7, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22168818

ABSTRACT

An intact keratin 5/keratin 14 intermediate filament cytoskeleton is vital for the integrity of basal keratinocytes and for the development and maintenance of epidermal structures. In patients with epidermolysis bullosa simplex Dowling-Meara (EBS-DM), heterozygous mutations in the keratin 14 gene in keratinocytes cause a cytoskeletal collapse leading to fragile cells susceptible to cellular stress. The primary aim of this work was to extend analysis of differentially expressed genes in an EBS-DM model cell line to obtain insights into the molecular consequences resulting from the keratin 14 mutation. In a first step, suppression subtractive hybridization (SSH), a powerful technology to enrich for differentially expressed genes, was used to identify genes whose up-regulation may be a direct or indirect result of the keratin 14 mutation, R125P. We discovered 55 candidate genes (SSH genes) that were further analysed by RTq-PCR. Of the 55 SSH genes, 14 (25.45%) were found to be congruently up-regulated. Bioinformatic analysis revealed significant enrichment of genes regulating epidermal development, migration, apoptosis and wound healing.


Subject(s)
Cell Differentiation/genetics , Cell Movement/genetics , Epidermolysis Bullosa Simplex/metabolism , Gene Expression Profiling/methods , Keratinocytes/metabolism , Wound Healing/genetics , Amino Acid Substitution/physiology , Apoptosis Regulatory Proteins/genetics , Cell Line, Transformed , Computational Biology/methods , DNA, Complementary/genetics , Epidermolysis Bullosa Simplex/genetics , Gene Expression/genetics , Humans , Keratin-14/genetics , Keratins/genetics , Real-Time Polymerase Chain Reaction , Ribosomal Proteins/genetics , Up-Regulation/genetics
16.
Exp Dermatol ; 21(5): 395-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22509840

ABSTRACT

Antibodies, specific to murine DEC205, can be used to target antigens to dendritic cells. The immunodominant domain of human type XVII collagen, hNC16A, was fused to this antibody (DEC-hNC16A) and was administered as expression plasmid by gene gun transfection with the aim of inducing tolerance to human type XVII collagen in a skin transplantation model. Mice transfected with DEC-hNC16A were challenged with skin grafts from transgenic mice engineered to express human type XVII collagen. Graft survival was either prolonged or grafts were accepted infinitely (33% and 16%, respectively) upon treatment with DEC-hNC16A while 100% of grafts were rejected in untreated controls. Graft acceptance was associated with the absence of a CD4+ infiltrate and a dense CD8+ T-cell infiltrate and was not strictly dependent on antibody production. Our results show that DEC-hNC16A targets dendritic cells in vivo leading to prolonged survival of transgenic skin grafts. This indicates that DEC205-targeting may be used for the induction of tolerance to skin antigens, which would increase the chances of successful skin gene therapy of epidermolysis bullosa patients.


Subject(s)
Autoantigens/immunology , Immune Tolerance/immunology , Langerhans Cells/immunology , Langerhans Cells/pathology , Non-Fibrillar Collagens/immunology , Skin Transplantation/immunology , Skin Transplantation/pathology , Animals , Autoantigens/genetics , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Genetic Therapy , Graft Rejection/immunology , Graft Rejection/pathology , Graft Survival/immunology , Humans , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , Models, Animal , Non-Fibrillar Collagens/genetics , Protein Structure, Tertiary , Transfection , Collagen Type XVII
17.
Pediatr Dermatol ; 28(6): 720-725, 2011.
Article in English | MEDLINE | ID: mdl-21854415

ABSTRACT

A 10-month-old boy presented with a history of a generalized cutaneous bullous eruption since 3 months of age. Emesis, flush, pruritus, and fatigue had accompanied relapsing episodes of sometimes extensive blistering. Histopathology showed dense dermal infiltrates of mast cells on hematoxylin and eosin and corroborating immunohistochemical staining. Laboratory examination revealed a markedly high level of serum tryptase. Based on these results and after consecutive staging, the patient was diagnosed with diffuse cutaneous bullous mastocytosis (BM). Mutation analysis detected a deletion mutation (del419) in C-Kit by direct exon sequencing. This rare entity must be considered in the differential diagnosis whenever a child presents with bullae and erosions. A crucial diagnostic hint is that rubbing of affected skin areas results in whealing (Darier's sign). A comprehensive diagnostic approach, advanced therapeutic strategies, regular follow-ups, and instruction of patients and relatives on prevention and prophylaxis are highly indicated.


Subject(s)
Epidermolysis Bullosa/diagnosis , Mastocytosis, Cutaneous/diagnosis , Dermatologic Agents , Diagnosis, Differential , Drug Therapy, Combination , Exons , Fatigue/diagnosis , Fatigue/genetics , Flushing/diagnosis , Flushing/genetics , Humans , Infant , Male , Mast Cells/drug effects , Mastocytosis, Cutaneous/genetics , Mastocytosis, Cutaneous/pathology , Proto-Oncogene Proteins c-kit/genetics , Pruritus/diagnosis , Pruritus/genetics , Sequence Deletion , Treatment Outcome , Tryptases/blood , Vomiting/diagnosis , Vomiting/genetics
18.
Exp Dermatol ; 19(10): 912-8, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20849533

ABSTRACT

Studies of skin aging are usually performed at the genomic level by investigating differentially regulated genes identified through subtractive hybridization or microarray analyses. In contrast, relatively few studies have investigated changes in protein expression of aged skin using proteomic profiling by two-dimensional (2-D) gel electrophoresis and mass spectrometry, although this approach at the protein level is suggested to reflect more accurately the aging phenotype. We undertook such a proteomic analysis of intrinsic human skin aging by quantifying proteins extracted and fluorescently labeled from sun-protected human foreskin samples pooled from 'young' and 'old' men. In addition, we analyzed these candidate gene products by 1-D and 2-D western blotting to obtain corroborative protein expression data, and by both real-time PCR (RT-PCR) and microarray analyses to confirm expression at the mRNA level. We discovered 30 putative proteins for skin aging, including previously unrecognized, post-translationally regulated candidates such as phosphatidyl-ethanolamine binding protein (PEBP) and carbonic anhydrase 1 (CA1).


Subject(s)
Foreskin/cytology , Foreskin/physiology , Gene Expression Profiling , Proteomics , Skin Aging/physiology , Adolescent , Adult , Aged , Blotting, Western , Carbonic Anhydrases/genetics , Carbonic Anhydrases/metabolism , Child , Child, Preschool , Electrophoresis, Gel, Two-Dimensional , Humans , Infant , Male , Mass Spectrometry , Middle Aged , Phosphatidylethanolamine Binding Protein/genetics , Phosphatidylethanolamine Binding Protein/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Young Adult
19.
Exp Dermatol ; 19(8): e241-50, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20497219

ABSTRACT

Keratin filaments form obligatory heterodimers consisting of one type I and one type II keratin that build the intermediate filaments (IF). These filaments mediate resilience and mechanical strength to epithelial cells and maintain tissue integrity. Specific type I/type II pairs are co-expressed in vivo and serve as markers for distinct tissue layers and cell differentiation states. Heterodimerization has been regarded the undisrupted hallmark of IF. We show now that recombinantly expressed cytokeratin 16 (K16) interacts with itself and forms homodimers even in denaturating SDS-PAGE analysis. Detailed FRET experiments in HaCaT keratinocytes were in accordance with our in vitro observations and showed clearly that K16 is able to form strong homodimers. Homotypic keratin interactions has been previously shown for keratin 17 (K17) and keratin 18 (K18) by Schnabel et al. (Biochim Biophys Acta, 1998: 1403: 158), and we now proved K16 to be the third type I keratin that is able to form homodimers.


Subject(s)
Intermediate Filaments/metabolism , Keratin-16/metabolism , Keratinocytes/metabolism , Aging/metabolism , Cell Line , Dimerization , Escherichia coli/genetics , Fluorescence Resonance Energy Transfer , Humans , Keratin-16/genetics , Keratin-17/metabolism , Keratin-18/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL